Nirogacestat

Drug Profile

Nirogacestat

Alternative Names: PF 3084014; PF-03084014

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Jules Bordet Institute; National Cancer Institute (USA); Pfizer
  • Class Amides; Antineoplastics; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma; Pancreatic cancer
  • No development reported Acute lymphoblastic leukaemia; Lymphoid leukaemia; Solid tumours; T-cell leukaemia
  • Discontinued Alzheimer's disease; Breast cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In adolescents, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Italy (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In adolescents, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoid-leukaemia(In adolescents, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Italy (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top